Boston Scientific (NYSE:BSX) Cut to “Neutral” at JPMorgan Chase & Co.

JPMorgan Chase & Co. cut shares of Boston Scientific (NYSE:BSX) from an overweight rating to a neutral rating in a research note released on Wednesday morning, MarketBeat.com reports. JPMorgan Chase & Co. currently has $46.00 price target on the medical equipment provider’s stock.

BSX has been the subject of several other research reports. Needham & Company LLC reduced their price objective on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday. Argus downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Barclays upgraded Boston Scientific to a “hold” rating in a report on Wednesday, October 7th. Truist Financial reduced their price target on Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Finally, Evercore decreased their price target on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Trading Down 1.8%

Shares of NYSE BSX opened at $41.93 on Wednesday. The business has a 50 day simple moving average of $44.78 and a 200 day simple moving average of $56.88. Boston Scientific has a 52 week low of $39.57 and a 52 week high of $105.65. The stock has a market cap of $60.77 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 1.05 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 earnings per share. On average, research analysts predict that Boston Scientific will post 3.17 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 189,522 shares of company stock valued at $9,157,810 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Boston Scientific in the second quarter worth about $5,534,781,000. Primecap Management Co. CA bought a new position in Boston Scientific during the second quarter worth about $2,156,233,000. Janus Henderson Group PLC grew its position in shares of Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after buying an additional 3,907,981 shares during the period. Amundi grew its position in shares of Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after buying an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after buying an additional 2,856,040 shares during the period. 89.07% of the stock is owned by institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.